EPFIA has called for a ban on re-packaging, stricter rules on auditing and controls in the supply chain, and the application of penalties for trafficking in counterfeits.

European Commission is in consultation to decide what legislation mandates to order to reduce counterfeit drugs, including: batch pedigrees, obligatory product seals, mass serialisation, mandatory audits and tight requirements for distribution stakeholders.

MHRA; General Manager, Michael Deats, will explain how the group is implementing strategic and operational measures designed to minimise the risk of counterfeit medicines and medical devices reaching patients through both the regulates and unregulated supply chains.

PSC is the annual event that has been working with industry and international regulatory bodies for years to disseminate important information to the industry and to bring the right people together to discuss realistic measures to deter counterfeiting of medicines and secure the supply chain.

Mark you calendar for this year’s must attend security event for pharmaceutical manufactures

“The annual Pharma Secure Chain conference is the industry dedicated event to discussing the important counterfeit issues in pharma” - Tom Bos, Organon

Previous International Leader Speaker Panel included: Harvey Bale, Director General, International Federation of Pharmaceutical Manufacturers Association (IFPMA) Valerio Reggi, Health Technology and Pharmaceuticals, World Health Organisation Graham Smith, Supply Chain Project Director, AstraZeneca & Chairperson, EFPIA Coding Group Walter Bergamaschi, Director General for Information Systems and Statistics, Italian Ministry of Health Laurent Moché, Director of Inspection, at the French Regulatory Agency AFSSaPS Josee Hansen, Chief Inspector, at the Dutch Health Care Inspectorate Els Pasmooij from Amgen Europe’s Security Programme: How they are strengthening their anti-counterfeiting toolbox Brad Elrod from Pfizer Christina Schütze, Merck Serono’s Andrew Jackson from Novartis Yves Juillet, President of Leem and Advisor to IFPMA and WHO IMPACT Ingrid Kempf, Senior Commercial Manager, Bristol Myers Squibb Lew Kontnik, Director Brand Protection and Business Continuity, Amgen Mark Davison, VP Pharmaceuticals, SICPA Product Security S.A. Andrew Jackson, Deputy Head, Global Corporate Security, Novartis Henk J. de Jong, Director International Scientific Relations, Servier Research Group, France Juval Aviv, President & CEO, Interfor Inc. Nimo Ahmed, Enforcement & Intelligence, Medicines and Healthcare products Regulatory Agency (MHRA) Benoit Godart, Seconded Expert, Financial & Property Crime Unit, EUROPOL Dieter Wurche, Technical Attaché, WORLD CUSTOMS ORGANISATION Monika Derecque-Pois, Secretary General, EUROPEAN ASSOCIATION OF WHOLESALERS (GIRP) Aaron Graham, Vice President and Chief Security Officer, Purdue Pharma David Weatherby, EPC Global European Adoption Programme Manager, GS1 UK Heinz Kobelt, Secretary General, European Association of Euro-Pharmaceutical Companies, (EAEPC) Geoff Power, Director, Packaging Security, Global Quality Assurance, GlaxoSmithKline Matthias Pfletschinger, Project Manager Track & Trace, Global Supply Chain Management, Novartis Pharma AG David Teale, Product Security Director, ASTRAZENECA Rob Whewell, Vice President Sales, AEGATE Alain Roudergues, Secretary General, CERP Rouen - SECOF